A randomized, double blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin--noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
The first recorded diagnosis of major depressive disorder, defined as a diagnosis of depressive episodes (ICD-10 code F32.x) along with antidepressant prescription (selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, serotonin noradrenaline reuptake inhibitors, or other antidepressants) during the follow-up period, was used as the primary outcome in the present study (Figure 1).
They showed substantial overlap of genetic risk factors shared between bipolar disorder, major depressive disorder and schizophrenia and less overlap between those conditions and autism and attention deficit-hyperactivity disorder (ADHD).
Major depressive disorder is characterized by symptoms that last for two weeks or more and include insomnia, impaired concentration, appetite disturbances, and feelings of sadness, fatigue, loss of pleasure, irritability, and hopelessness.
Major depressive disorder or mental disorder is a serious and disabling illness in the world, characterized by sad mood and loss of interest, associated with disability and comorbidity on individuals and their families.